Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22225868 | 0.84 | KMT2A (0.56) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3307080 | 0.77 | KMT2A (0.68) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL18965315 | 0.76 | DNM1 (0.51) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL18964880 | 0.76 | DNM1 (0.51) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL21466938 | 0.73 | MAPK1 (0.68) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3188818 | 0.73 | KMT2A (0.62) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL23774829 | 0.73 | MEN1 (0.60) | KMT2AMEN1LMNAALDH1A1MAPK1 | |
| SCHEMBL21466931 | 0.73 | MEN1 (0.60) | KMT2AMEN1LMNAALDH1A1MAPK1 | |
| SCHEMBL7927457 | 0.73 | MEN1 (0.60) | KMT2AMEN1LMNAALDH1A1MAPK1 | |
| SCHEMBL24328242 | 0.72 | KMT2A (0.60) | KDM4EKMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-10017471-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-9814698-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170095446-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170029370-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095446-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, UBE2V1 | KDM4E 497/4885KMT2A 723/4885MEN1 3802/4885 |
| US-10017471-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, ADRM1 | KDM4E 900/4885KMT2A 1022/4885MEN1 3223/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | KDM4E 1046/4885KMT2A 977/4885MEN1 2841/4885 |
| US-20170029370-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, ADRM1 | KDM4E 900/4885KMT2A 1022/4885MEN1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.